How to Tell When A Drug Company Fibs About Clinical Trial Results
By Adam Feuerstein,
The Street
| 07. 03. 2012
Osiris Therapeutics
"disappeared" important data when the company announced results Monday
from a mid-stage study of its stem cell therapy Prochymal in heart
attack patients.
Naturally, Osiris didn't come out and tell investors that it was
issuing a misleading press release on the Prochymal heart attack study.
Instead, the company claimed the study was a success. That's not true.
Figuring out Osiris' deception wasn't that difficult if you know how to
parse the language of clinical trial results and look at independent
sources of information for the truth.
Ride along with me as I pick apart Osiris' statements regarding the Prochymal heart attack study.
Interpreting clinical trial results with a skeptical eye is a crucial
tool for all biotech investors, so apply these skills universally
whenever a drug or biotech company tries to convince you that its drug
works. Hopefully, you'll find most companies are telling the truth, but
sadly and too often, bullish pronouncements about boffo clinical trial
data are just spin jobs ginned up to plaster over problems and bad data.
Here's what Osiris issued Monday:
Osiris...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...